Hamburg, Germany - 08 July 2014: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today an exclusive strategic collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in several disease areas through the combination of the relevant platforms of both organisations for internal and external drug discovery projects.
This alliance expands Evotec's already powerful drug discovery platform with access to a broad range of complementary and highly innovative platforms and capabilities to progress own innovate projects and provides additional capabilities for customers and partners of Evotec and IME, respectively. The deal follows the joint decision of Evotec, Fraunhofer-Gesellschaft and the City of Hamburg to integrate the European ScreeningPort GmbH into the IME thereby forming the first Fraunhofer life science institution in the City of Hamburg.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are looking forward to partner with Fraunhofer IME and are excited about the potential of this alliance. The IME has an impressive track record for product development and provides an ideal basis for collaborating with one of the strongest science organisations in Germany and beyond. This adds another footprint in Europe of our EVT Innovate programmes as we have with US based academic institutions."
Prof. Dr Rainer Fischer, Senior Executive Director at the Fraunhofer IME stated: "This collaboration constitutes a win-win situation through the project-specific combination of first-in-class capabilities. In particular, Evotec's medicinal chemistry and expertise will add value to our own, our joint and our partner's programmes. We look forward to collaborate with an experienced player in the life science industry on several layers now and in the future."